Allergic Rhinitis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Allergic Rhinitis – Drugs In Development, 2023’, provides an overview of the Allergic Rhinitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis
- The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects
- The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbbVie IncAdvagene Biopharma Co Ltd
ALK-Abello AS
Alkem Laboratories Ltd
Allergy Therapeutics Plc
Allovate LLC
AOBiome LLC
ARS Pharmaceuticals Inc
AtoGen Co Ltd
Bai Shuo Beijing Pharmaceutical Technology Co Ltd
Beijing Puqi Pharmaceutical Technology Co Ltd
Cellix Bio Pvt Ltd
Changchun Lanjiang Pharmaceutical Technology Co Ltd
Chiba University
Chrysalis BioTherapeutics Inc
CSPC Pharmaceutical Group Ltd
DMS Imaging SA
DongKoo Bio & Pharma Co Ltd
Emergo Therapeutics Inc
EmphyCorp Inc
EMS SA
Eurofarma Laboratorios SA
Faes Farma SA
FunPep Co Ltd
GBC-HpVac SA
GENUONE Sciences Inc
Glenmark Pharmaceuticals Ltd
Green Immunoscience Ltd
HAL Allergy BV
Hangzhou Vitan Pharmaceutical Technology Co Ltd
Inimmune Corp
Inmunotek SL
Johns Hopkins University
KeyMed Biosciences Inc
Korea Research Institute of Chemical Technology
Kyung Hee University
LAmAb Biologics Inc
Liminal BioSciences Inc
Marinomed Biotech AG
MD Healthcare Inc
Mitsubishi Tanabe Pharma Corp
Nanjing Drum Tower Hospital
Nasus Pharma Ltd
NeuCen BioMed Co Ltd
Oneness Biotech Co Ltd
Palo Alto pharmaceuticals Inc
Paradigm Biopharmaceuticals Ltd
Pediatrix Therapeutics Inc
Pleros Therapeutics Inc
Raphas Co Ltd
Regeneron Pharmaceuticals Inc
Revolo Biotherapeutics Ltd
Roxall Medizin GmbH
Sama Pharm Co Ltd
Sedor Pharmaceuticals LLC
Shiga University of Medical Science
Shouyao Holding Co Ltd
Siolta Therapeutics Inc
Stallergenes Greer Ltd
Synokem Pharmaceuticals Ltd
The National Institute of Allergy and Infectious Diseases
Tianchen Biopharmaceutical (Suzhou) Co Ltd
United Biomedical Inc
University of Queensland
Vactech Oy
Wuhan Yicheng Biotechnology Co Ltd
Yuyu Pharma Inc
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhujiang Hospital of Southern Medical University
Zonhon Biopharma Institute Inc
Zydus Lifesciences Ltd